NPS PhIII data bolsters hypoparathyroidism drug
12:20 EDT 26 Jun 2012 | SCRIP
NPS Pharmaceuticals says that data from the double-blind, placebo-controlled Phase III REPLACE study of Natpara (formerly NPSP558) reinforce its belief that Natpara could be the first parathyroid hormone replacement therapy for adults with.....
Original Article: NPS PhIII data bolsters hypoparathyroidism drug
More From BioPortfolio on "NPS PhIII data bolsters hypoparathyroidism drug"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
